Drug Name Mix-Ups Of Aricept/Azilect And Neulasta/Lunesta Under Investigation By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Confusion has occurred with oral and written orders, the Institute for Safe Medication Practices Medication Safety Alert reports.
You may also be interested in...
FDA Seeks To End Industry’s Use Of Error-Prone Medical Abbreviations
In partnership with PhRMA, FDA and the Institute for Safe Medication Practices have launched a campaign to prevent error-prone notation from appearing in labels and advertisements.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.